Literature DB >> 25232239

Interleukin 28B genetic polymorphism and hepatitis B virus infection.

Toru Takahashi1.   

Abstract

Interleukin (IL) 28B genetic polymorphism is significantly associated with the sustained virological response rate in patients with chronic hepatitis C treated with pegylated interferon-α (PEG-IFN) plus ribavirin and with spontaneous hepatitis C virus clearance. However, a consensus on the relationship between IL28B genetic polymorphism and the favorable outcome of chronic hepatitis B virus infection defined by hepatitis B e antigen seroconversion, and/or hepatitis B surface antigen seroclearance in patients treated with interferon or PEG-IFN has not been reached. Several reports failed to show a positive association, while some studies demonstrated a positive association in certain subject settings. More prospective studies including large cohorts are needed to determine the possible association between IL28B genetic polymorphism and the outcome of interferon or PEG-IFN treatment for chronic hepatitis B.

Entities:  

Keywords:  Hepatitis B virus; Interferon; Interleukin 28B; Pegylated interferon; Polymorphism

Mesh：

Substances：

Year:  2014        PMID： 25232239      PMCID： PMC4161790          DOI： 10.3748/wjg.v20.i34.12026

Source DB:  PubMed          Journal:  World J Gastroenterol        ISSN： 1007-9327            Impact factor:   5.742


  36 in total

1.  Evaluation of susceptibility locus for response to interferon-α based therapy in chronic hepatitis B patients in Chinese.

Authors:  Xiaopan Wu; Zhenhui Xin; Xilin Zhu; Liping Pan; Zhuo Li; Hui Li; Ying Liu
Journal:  Antiviral Res       Date:  2011-12-19       Impact factor: 5.970

2.  IL28B polymorphism does not determine outcomes of hepatitis B virus or HIV infection.

Authors:  Maureen P Martin; Ying Qi; James J Goedert; Shehnaz K Hussain; Gregory D Kirk; W Keith Hoots; Susan Buchbinder; Mary Carrington; Chloe L Thio
Journal:  J Infect Dis       Date:  2010-10-26       Impact factor: 5.226

3.  Effect of host and viral factors on hepatitis B e antigen-positive chronic hepatitis B patients receiving pegylated interferon-α-2a therapy.

Authors:  Tai-Chung Tseng; Ming-Lung Yu; Chun-Jen Liu; Chih-Lin Lin; Yi-Wen Huang; Ching-Sheng Hsu; Chen-Hua Liu; Stephanie Fang-Tzu Kuo; Corinna Jen-Hui Pan; Sheng-Shun Yang; Chien-Wei Su; Pei-Jer Chen; Ding-Shinn Chen; Jia-Horng Kao
Journal:  Antivir Ther       Date:  2011

4.  Hepatitis C virus induces interferon-λ and interferon-stimulated genes in primary liver cultures.

Authors:  Svetlana Marukian; Linda Andrus; Timothy P Sheahan; Christopher T Jones; Edgar D Charles; Alexander Ploss; Charles M Rice; Lynn B Dustin
Journal:  Hepatology       Date:  2011-12       Impact factor: 17.425

5.  Hepatic ISG expression is associated with genetic variation in interleukin 28B and the outcome of IFN therapy for chronic hepatitis C.

Authors:  Masao Honda; Akito Sakai; Tatsuya Yamashita; Yasunari Nakamoto; Eishiro Mizukoshi; Yoshio Sakai; Taro Yamashita; Mikiko Nakamura; Takayoshi Shirasaki; Katsuhisa Horimoto; Yasuhito Tanaka; Katsushi Tokunaga; Masashi Mizokami; Shuichi Kaneko
Journal:  Gastroenterology       Date:  2010-04-29       Impact factor: 22.682

6.  Polymorphisms near IL28B and serologic response to peginterferon in HBeAg-positive patients with chronic hepatitis B.

Authors:  Milan J Sonneveld; Vincent W-S Wong; Andrea M Woltman; Grace L H Wong; Yilmaz Cakaloglu; Stefan Zeuzem; Erik H C J Buster; Andre G Uitterlinden; Bettina E Hansen; Henry L Y Chan; Harry L A Janssen
Journal:  Gastroenterology       Date:  2011-11-19       Impact factor: 22.682

7.  Expression and gene polymorphisms of interleukin 28B and hepatitis B virus infection in a Chinese Han population.

Authors:  Wanyu Li; Yanfang Jiang; Qinglong Jin; Xiaodong Shi; Jinglan Jin; Yanhang Gao; Yu Pan; Hong Zhang; Jing Jiang; Junqi Niu
Journal:  Liver Int       Date:  2011-03-30       Impact factor: 5.828

8.  Phase 1b study of pegylated interferon lambda 1 with or without ribavirin in patients with chronic genotype 1 hepatitis C virus infection.

Authors:  Andrew J Muir; Mitchell L Shiffman; Atif Zaman; Boris Yoffe; Andrew de la Torre; Steven Flamm; Stuart C Gordon; Paul Marotta; John M Vierling; Juan Carlos Lopez-Talavera; Kelly Byrnes-Blake; David Fontana; Jeremy Freeman; Todd Gray; Diana Hausman; Naomi N Hunder; Eric Lawitz
Journal:  Hepatology       Date:  2010-09       Impact factor: 17.425

9.  IL28B rs12979860 polymorphism does not influence outcomes of hepatitis B virus infection.

Authors:  L J Peng; J S Guo; Z Zhang; H Shi; J Wang; J Y Wang
Journal:  Tissue Antigens       Date:  2012-01-13

10.  IL28B genotype is associated with differential expression of intrahepatic interferon-stimulated genes in patients with chronic hepatitis C.

Authors:  Thomas J Urban; Alexander J Thompson; Shelton S Bradrick; Jacques Fellay; Detlef Schuppan; Kenneth D Cronin; Linda Hong; Alexander McKenzie; Keyur Patel; Kevin V Shianna; John G McHutchison; David B Goldstein; Nezam Afdhal
Journal:  Hepatology       Date:  2010-10-07       Impact factor: 17.425
View more
  3 in total

1.  Impact of IL28B and OAS gene family polymorphisms on interferon treatment response in Caucasian children chronically infected with hepatitis B virus.

Authors:  Krzysztof Domagalski; Małgorzata Pawłowska; Agnieszka Zaleśna; Małgorzata Pilarczyk; Paweł Rajewski; Waldemar Halota; Andrzej Tretyn
Journal:  World J Gastroenterol       Date:  2016-11-07       Impact factor: 5.742

Review 2.  The Role of Interferon-λ Locus Polymorphisms in Hepatitis C and Other Infectious Diseases.

Authors:  Samantha J Griffiths; Cory M Dunnigan; Clark D Russell; Jürgen G Haas
Journal:  J Innate Immun       Date:  2015-01-23       Impact factor: 7.349

Review 3.  Gene-disease association with human IFNL locus polymorphisms extends beyond hepatitis C virus infections.

Authors:  S Chinnaswamy
Journal:  Genes Immun       Date:  2016-06-09       Impact factor: 2.676
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.